# A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

> **NCT06337643** · PHASE1 · UNKNOWN · sponsor: **Matrivax Research and Development Corporation** · enrollment: 75 (estimated)

## Conditions studied

- Pneumococcal Vaccine

## Interventions

- **BIOLOGICAL:** MVX01
- **BIOLOGICAL:** MVX01 Placebo

## Key facts

- **NCT ID:** NCT06337643
- **Lead sponsor:** Matrivax Research and Development Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-07
- **Primary completion:** 2024-04-16
- **Final completion:** 2024-04-16
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06337643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06337643, "A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06337643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*